{"nctId":"NCT00105079","briefTitle":"GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection","startDateStruct":{"date":"2005-04"},"conditions":["HIV Infections"],"count":337,"armGroups":[{"label":"saquinavir/ritonavir","type":"EXPERIMENTAL","interventionNames":["Drug: saquinavir [Invirase]","Drug: Emtricitabine/tenofovir disoproxil fumarate","Drug: Ritonavir"]},{"label":"lopinavir/ritonavir","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Lopinavir/ritonavir","Drug: Emtricitabine/tenofovir disoproxil fumarate"]}],"interventions":[{"name":"saquinavir [Invirase]","otherNames":["Invirase"]},{"name":"Lopinavir/ritonavir","otherNames":["Kaletra"]},{"name":"Emtricitabine/tenofovir disoproxil fumarate","otherNames":["Truvada"]},{"name":"Ritonavir","otherNames":["Norvir"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* adult patients \\>=18 years of age;\n* chronic HIV-1 infection;\n* treatment-naive;\n* HIV-1 RNA viral load \\>=10,000copies/mL;\n* women of childbearing potential must have a negative pregnancy test, and must use reliable contraception for the duration of the study and for 90 days after the last dose of study medication.\n\nExclusion Criteria:\n\n* females who are pregnant or breastfeeding;\n* active hepatitis B infection;\n* previous treatment with antiretroviral medication;\n* patients who have received an investigational drug within the last 4 weeks.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Patients With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) Viral Load <50 Copies/mL","description":"The primary objective of this study was to evaluate the efficacy of saquinavir/ritonavir BID plus emtricitabine/tenofovir QD versus lopinavir/ritonavir BID plus emtricitabine/tenofovir QD in treatment-naïve HIV-1 infected adults.\n\nBlood samples for HIV-1 RNA viral load measurement were collected at the Week 48 clinic visit. The number of participants with HIV-1 RNA results \\<50 copies/mL is reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"108","spread":null},{"groupId":"OG001","value":"108","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"62","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With HIV-1 RNA Viral Load <50 and <400 Copies/mL","description":"The secondary objectives of the study were to evaluate the safety, adherence, and tolerability of saquinavir/ritonavir BID plus emtricitabine/tenofovir QD versus lopinavir/ritonavir BID plus emtricitabine/tenofovir QD in treatment-naïve HIV-1 infected adults.\n\nBlood samples for HIV-1 RNA viral load measurement were collected at the Week 48 clinic visit. The number of participants with HIV-1 RNA results \\<50 copies/mL and the number of participants with HIV-1 RNA results \\<400 copies/mL are reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"108","spread":null},{"groupId":"OG001","value":"108","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"121","spread":null},{"groupId":"OG001","value":"127","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HIV-1 RNA Viral Load","description":"Descriptive statistics for change from baseline in log10 transformed plasma HIV-1 RNA load (copies/mL) were presented by treatment arm. Logarithmic transformation (base 10) was applied to HIV-1 RNA viral load at baseline and at each study visit. Change from baseline in plasma HIV-1 RNA was derived as follows: Change from baseline = Log10 (HIV-1 RNA at week x) - Log10 (HIV-1 RNA at baseline)","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.20","spread":null},{"groupId":"OG001","value":"5.17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.80","spread":null},{"groupId":"OG001","value":"1.83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.39","spread":null},{"groupId":"OG001","value":"-3.36","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Cluster Differentiation Antigen 4 Positive (CD4+) Lymphocyte Count","description":"Summary statistics for change from baseline in CD4+ lymphocyte count were presented by treatment arm. Change from baseline in CD4+ lymphocyte count was derived as follows: Change from baseline = (CD4+ count at week x) - (CD4+ count at baseline).","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"141.5","spread":null},{"groupId":"OG001","value":"142.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"319.0","spread":null},{"groupId":"OG001","value":"348.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"178.0","spread":null},{"groupId":"OG001","value":"204.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Assessed for Adverse Events (AEs)","description":"Detailed information for Adverse Events and Serious Adverse Events will be represented in the SAE/AE section of PRS.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"163","spread":null},{"groupId":"OG001","value":"168","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Who Discontinued Treatment Due to Abnormal Laboratory Parameters","description":"Routine clinical testing, including hematology and standard chemistry panel was performed at all study visits. Laboratory tests for a fasting lipid profile and fasting insulin determination were obtained at baseline, weeks 24 and 48, and the 4-week follow-up visit. The number of participants who discontinued treatment due to an abnormal laboratory result at any visit is reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":24,"n":163},"commonTop":["Diarrhoea","Nausea","Vomiting","Upper respiratory tract infection","Fatigue"]}}}